| Literature DB >> 31181664 |
Annunziata D'Alessandro1, Luisa Lampignano2, Giovanni De Pergola3.
Abstract
In the last decade, a number of meta-analyses of mostly observational studies evaluated the relation between the intake of food groups and the risk of noncommunicable diseases (NCDs). In this study, we systematically reviewed dose-response meta-analyses of prospective studies with the aim to derive the quantities of food to consume to attain a protective (Mediterranean food) or a non-adverse (non-Mediterranean food) effect toward selected NCDs such as cardiovascular disease (CVD) including coronary heart disease (CHD) and stroke, type 2 diabetes (T2DM), colorectal (CRC) and breast cancer. These derived quantities, wherever possible, were suggested for a quantification of food servings of the Mediterranean Diet Pyramid proposed for Italian People (MDPPI). This pyramid came from the Modern Mediterranean Diet Pyramid developed in 2009 for Italian people. A weekly menu plan was built on the advice about frequency of intakes and serving sizes of such pyramid and the nutritional composition of this diet was compared with the Reference Italian Mediterranean Diet followed in 1960 in Nicotera. The diet built according the advice of MDPPI was very similar to that of Nicotera in the late 1950s that has been chosen as Italian Reference Mediterranean Diet with the exception of percentage of energy provided by cereals that was lower and of fruits and vegetables that was higher. Saturated fatty acids were only the 6% of daily energy intake. Also the Mediterranean Adequacy Index (MAI) was very similar to that of the aforementioned diet.Entities:
Keywords: Mediterranean diet; Mediterranean diet pyramid
Mesh:
Year: 2019 PMID: 31181664 PMCID: PMC6628543 DOI: 10.3390/nu11061296
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Proposal of Mediterranean Diet Pyramid for Italian People [9].
Summary of linear dose-response meta-analyses of prospective studies on whole grain intake and CVD, CHD, stroke, T2DM and CRC.
| Authors, Year, Reference | No. of Studies | Each Increment Intake Per Day | RR (95% CI) | I2 Statistic | Begg’s or Egger’s Test | |
|---|---|---|---|---|---|---|
| Benisi-Kohansal 2016 [ | 3 | 90 g | CVD mortality 0.83 (0.76–0.91) * | 0.00% | 0.860 | NR |
| Chen 2016 [ | 10 | 50 g | CVD mortality 0.70 (0.61–0.79) | 64.80% | 0.002 | 0.370/0.140 |
| Li 2016 [ | 8 | 30 g | CVD mortality 0.95 (0.92–0.98) | 68.60% | <0.001 | 0.276/0.202 |
| Wei 2016 [ | 8 | 90 g | CVD mortality 0.74 (0.66–0.83) | 76.30% | <0.001 | 0.107/0.834 |
| Aune 2016 [ | 10 | 90 g | CVD 0.78 (0.73–0.85) | 40.00% | 0.090 | 0.310 |
| Bechthold 2017 [ | 5 | 30 g | CHD 0.95 (0.92–0.98) | 46.00% | 0.110 | NR |
| Aune 2016 [ | 7 | 90 g | CHD 0.81 (0.75–0.87) | 9.00% | 0.360 | 0.110 |
| Bechthold 2017 [ | 4 | 30 g | Stroke 0.99 (0.95–1.03) | 65.00% | 0.040 | NR |
| Aune 2016 [ | 6 | 90 g | Stroke 0.88 (0.75–1.03) | 56.00% | 0.040 | 0.010 |
| Schwingshackl 2017 [ | 12 | 30 g | T2DM 0.87 (0.82–0.93) | 91.00% | NR | NR |
| Aune 2011 [ | 6 | 90 g | CRC 0.83 (0.78–0.89) | 18.00% | 0.300 | 1.000/0.540 |
| Vieira 2017 [ | 6 | 90 g | CRC 0.83 (0.79–0.89) | 18.00% | 0.300 | NS |
| Schwingshackl 2018 [ | 9 | 30 g | CRC 0.95 (0.93–0.97) | 58.00% | 0.0200 | NR |
* specific whole grains; CVD, cardiovascular disease; CHD, coronary heart disease; T2DM, type 2 diabetes mellitus; CRC, colorectal cancer; RR, relative risk; NR, not reported; NS, not significant.
Summary of linear dose-response meta-analyses of prospective studies on vegetable intake and CVD, CHD, stroke, T2DM, CRC, breast cancer.
| Authors, Year, Reference | No. of Studies | Each Increment Intake Per Day | RR (95% CI) | I2 Statistic | Begg’s or Egger’s Test | |
|---|---|---|---|---|---|---|
| Aune 2017 [ | 14 | 200 g | CVD 0.90 (0.87–0.93) | 11.50% | 0.330 | 0.530 |
| Gan 2015 [ | 13 | 400 g | CHD 0.82 (0.73–0.92) | 35.60% | 0.068 | 0.880/0.381 |
| Aune 2017 [ | 20 | 200 g | CHD 0.84 (0.79–0.90) | 60.60% | <0.0001 | 0.001 |
| Bechthold 2017 [ | 14 | 100 g | CHD 0.97 (0.96–0.99) | 12.00% | 0.320 | NR |
| Aune 2017 [ | 13 | 200 g | Stroke 0.87 (0.79–0.96) | 63.40% | 0.001 | 0.150 |
| Bechthold 2017 [ | 10 | 100 g | Stroke 0.92 (0.86–0.98) | 79.00% | <0.001 | NR |
| Li 2014 [ | 5 | 106 g | T2DM 0.98 (0.89–1.08) | 45.80% | 0.117 | 0.117 |
| Wu 2015 [ | 7 | 106 g | T2DM 0.98 (0.95–1.01) | 78.30% | 0.000 | 0.130/0.150 |
| Schwingshackl 2017 [ | 11 | 100 g | T2DM 0.98 (0.96–1.00) | 62.00% | NR | NS |
| Vieira 2017 [ | 11 | 100 g | CRC 0.98 (0.96–0.99) | 0.00% | 0.480 | NS |
| Schwingshackl 2018 [ | 15 | 100 g | CRC 0.97 (0.96–0.98) | 0.00% | 0.640 | 0.530 |
| Aune 2012 [ | 9 | 200 g | Breast cancer 1.00 (0.95–1.06) | 17.00% | 0.290 | NR |
CVD, cardiovascular disease; CHD, coronary heart disease; T2DM, type 2 diabetes mellitus; CRC, colorectal cancer; RR, relative risk; NR, not reported; NS, not significant.
Summary of linear dose-response meta-analyses of prospective studies on fruit intake and CVD, CHD, stroke, T2DM, CRC, breast cancer.
| Authors, Year, Reference | No. of Studies | Each Increment Intake Per Day | RR (95% CI) | I2 Statistic | Begg’s or Egger’s Test | |
|---|---|---|---|---|---|---|
| Aune 2017 [ | 17 | 200 g | CVD 0.87 (0.82–0.92) | 79.10% | <0.0001 | 0.410 |
| Gan 2015 [ | 15 | 300 g | CHD 0.84 (0.75–0.93) | 31.70% | 0.0780 | 0.367/0.591 |
| Aune 2017 [ | 24 | 200 g | CHD 0.90 (0.86–0.94) | 43.70% | 0.0100 | 0.040 |
| Bechthold 2017 [ | 13 | 100 g | CHD 0.94 (0.90–0.97) | 71.00% | <0.0010 | NR |
| Aune 2017 [ | 16 | 200 g | Stroke 0.82 (0.74–0.90) | 72.90% | <0.0001 | 0.620 |
| Bechthold 2017 [ | 10 | 100 g | Stroke 0.90 (0.84–0.97) | 86.00% | 0.0010 | NR |
| Li 2014 [ | 7 | 106 g | T2DM 0. 94 (0.89–1.00) | 0.00% | 0.059 | NR |
| Wu 2015 [ | 9 | 106 g | T2DM 0.99 (0.97–1.00) | 18.60% | 0.278 | 0.470/0.680 |
| Schwingshackl 2017 [ | 13 | 100 g | T2DM 0.98 (0.97–1.00) | 21.00% | NR | NS |
| Vieira 2017 [ | 13 | 100 g | CRC 0.96 (0.93–1.00) | 68.00% | <0.0001 | NS |
| Schwingshackl et al. 2018 [ | 16 | 100 g | CRC 0.97 (0.95–0.99) | 61.00% | <0.0010 | 0.120 |
| Aune 2012 [ | 10 | 200 g | Breast cancer 0.94 (0.89–1.00) | 39.00% | 0.1000 | NR |
CVD, cardiovascular disease; CHD, coronary heart disease; T2DM, type 2 diabetes mellitus; CRC, colorectal cancer; RR, relative risk; NR, not reported; NS, not significant.
Summary of linear dose-response meta-analyses of prospective studies on milk intake and CVD, CHD, stroke, T2DM, CRC, and breast cancer.
| Authors, Year, Reference | No. of Studies | Each Increment Intake Per Day | RR (95% CI) | I2 Statistic | Begg’s or Egger’s Test | |
|---|---|---|---|---|---|---|
| Soedamah-Muthu 2011 [ | 4 | 200 mL | CVD 0.94 (0.89–0.99) | 0.00% | 0.5020 | NR |
| Guo 2017 [ | 12 | 244 g | CVD 1.01 (0.93–1.10) | 92.40% | <0.0010 | 0.449 |
| Soedamah-Muthu 2011 [ | 6 | 200 mL | CHD 1.00 (0.96–1.04) | 26.90% | 0.2330 | NR |
| Mullie 2016 [ | 9 | 200 mL | CHD 1.01 (0.98–1.05) | 16.00% | 0.3000 | 0.680/0.050 |
| Guo 2017 [ | 12 | 244 g | CHD 1.01 (0.96–1.06) | 45.50% | 0.0430 | 0.397 |
| Soedamah-Muthu 2011 [ | 6 | 200 mL | Stroke 0.87 (0.72–1.07) | 94.60% | 0.0000 | NR |
| de Goede 2016 [ | 14 | 200 g | Stroke 0.93 (0.88–0.98) | 86.00% | <0.0010 | 0.060 |
| Mullie 2016 [ | 10 | 200 mL | Stroke 0.91 (0.82–1.02) | 92.00% | <0.0100 | 0.530/0.050 |
| Aune 2013 [ | 7 | 200 g | T2DM 0.87 (0.72–1.04) | 93.60% | <0.0001 | 0.410 |
| Gao 2013 [ | 8 | 200 g | T2DM incidence 0.89 (0.79–1.01) | 66.30% | 0.0050 | NR |
| Gijsbers 2016 [ | 12 | 200 g | T2DM incidence 0.97 (0.93–1.02) | 57.40% | 0.0070 | 0.071 |
| Aune 2012 [ | 9 | 200 g | CRC 0.90 (0.85–0.94) | 0.00% | 0.6200 | 0.840/0.860 |
| Vieira 2017 [ | 9 | 200 g | CRC 0.94 (0.92–0.96) | 0.00% | 0.9700 | NS |
| Dong 2011 [ | 9 | 200 g | Breast cancer 0.98 (0.95–1.01) | NR | >0.3000 | >0.050 |
| Wu 2016 [ | 11 | 200 g | Breast cancer incidence 0.97 (0.93–1.01) | 36.40% | NR | 0.436/0.355 |
CVD, cardiovascular disease; CHD, coronary heart disease; T2DM, type 2 diabetes mellitus; CRC, colorectal cancer; RR, relative risk; NR, not reported; NS, not significant.
Summary of linear dose-response meta-analyses of prospective studies on cheese intake and CVD, CHD, stroke, T2DM, and CRC.
| Authors, Year, Reference | No. of Studies | Each Increment Intake Per Day | RR (95% CI) | I2 Statistic | Begg’s or Egger’s Test | |
|---|---|---|---|---|---|---|
| Chen 2017 [ | 7 | 50 g | CVD 0.92 (0.83–1.02) | 16.90% | 0.301 | >0.100 |
| Guo 2017 [ | 11 | 10 g | CVD 0.98 (0.95–1.00) | 82.60% | <0.001 | NR |
| Chen 2017 [ | 8 | 50 g | CHD 0.90 (0.84–0.95) | 0.00% | 0.444 | 0.170/0.040 |
| Guo 2017 [ | 10 | 10 g | CHD 0.99 (0.97–1.02) | 40.30% | 0.089 | 0.273 |
| Chen 2017 [ | 5 | 50 g | Stroke 0.94 (0.84–1.04) | 63.70% | 0.026 | >0.10 |
| de Goede 2016 [ | 7 | 40 g | Stroke 0.97 (0.94–1.01) | 31.20% | 0.179 | NR |
| Aune 2013 [ | 8 | 50 g | T2DM 0.92 (0.86–0.99) | 0.00% | 0.790 | 0.740 |
| Gao 2013 [ | 7 | 30 g | T2DM incidence 0.80 (0.69–0.93) | 59.00% | 0.020 | NR |
| Gijsbers 2016 [ | 13 | 10 g | T2DM incidence 1.00 (0.99–1.02) | 61.70% | 0.002 | 0.880 |
| Aune 2012 [ | 7 | 50 g | CRC 0.96 (0.83–1.12) | 28.00% | 0.220 | NR |
| Vieira 2017 [ | 7 | 50 g | CRC 0.94 (0.87–1.02) | 10.00% | 0.360 | NS |
CVD, cardiovascular disease; CHD, coronary heart disease; T2DM, type 2 diabetes mellitus; CRC, colorectal cancer; RR, relative risk; NR, not reported; NS, not significant.
Summary of linear dose-response meta-analyses of prospective studies on yogurt intake and CVD, CHD, stroke, T2DM, and breast cancer.
| Authors, Year, Reference | No. of Studies | Each Increment Intake Per Day | RR (95% CI) | I2 Statistic | Begg’s or Egger’s Test | |
|---|---|---|---|---|---|---|
| Guo 2017 [ | 3 | 50 g | CVD 1.03 (0.97–1.09) | 0.00% | 0.499 | NR |
| Guo 2017 [ | 3 | 50 g | CHD 1.03 (0.97–1.09) | 0.00% | 0.685 | NR |
| de Goede 2016 [ | 3 | 100 g | Stroke 1.02 (0.90–1.17) | 47.80% | 0.147 | NR |
| Aune 2013 [ | 7 | 200 g | T2DM 0.78 (0.60–1.02) | 69.90% | 0.003 | 0.370 |
| Gao 2013 [ | 7 | 50 g | T2DM incidence 0.91 (0.82–1.00) | 74.00% | 0.001 | NR |
| Gijsbers 2016 [ | 12 | 50 g | T2DM incidence 0.94 (0.90–0.97) | 73.30% | 0.000 | 0.180 |
| Wu 2016 [ | 3 | 200 g | Breast cancer incidence 0.87 (0.72–1.06) | 0.00% | NR | 1.000/0.488 |
CVD, cardiovascular disease; CHD, coronary heart disease; T2DM, type 2 diabetes mellitus; RR, relative risk; NR, not reported.
Summary of linear dose-response meta-analyses of prospective studies on nut intake and CVD, CHD, stroke, T2DM, CRC, breast cancer.
| Authors, Year, Reference | No. of Studies | Each Increment Intake Per Day | RR (95% CI) | I2 Statistic | Begg’s or Egger’s Test | |
|---|---|---|---|---|---|---|
| Luo 2014 [ | 4 | 28 g | CVD incidence 0.71 (0.59–0.85) | 48.80% | 0.119 | 0.090 |
| Aune 2016 [ | 11 | 28 g | CVD 0.80 (0.72–0.89) | 56.00% | 0.001 | NR |
| Grosso 2015 [ | 5 | 28 g | CVD mortality 0.61 (0.42–0.91) | 75.00% | NR | NR |
| Aune 2016 [ | 11 | 28 g | CHD 0.71 (0.63–0.80) | 47.00% | 0.040 | 0.280 |
| Bechthold 2017 [ | 4 | 28 g | CHD 0.67 (0.43–1.05) | 85.00% | 0.001 | NR |
| Aune 2016 [ | 11 | 28 g | Stroke 0.93 (0.83–1.05) | 14.00% | 0.310 | 0.300 |
| Bechthold 2017 [ | 6 | 28 g | Stroke 0.99 (0.84–1.17) | 45.00% | 0.110 | NR |
| Luo 2014 [ | 4 | 28 g | T2DM incidence 1.03 (0.91–1.16) | 63.90% | 0.040 | 0.810 |
| Schwingshackl 2017 [ | 7 | 28 g | T2DM 0.89 (0.71–1.12) | 77.00% | NR | NR |
| Schwingshackl 2018 [ | 4 | 28 g | CRC 0.96 (0.76–1.21) | 25.00% | 0.260 | NR |
| Wu 2016 [ | 3 | 28 g | Breast cancer incidence 0.96 (0.84–1.09) | 0.00% | NR | 0.100/0.955 |
CVD, cardiovascular disease; CHD, coronary heart disease; T2DM, type 2 diabetes mellitus; CRC, colorectal cancer; RR, relative risk; NR, not reported.
Summary of linear dose-response meta-analyses of prospective studies on olive oil intake and CHD, stroke, T2DM.
| Authors, Year, Reference | No. of Studies | Each Increment Intake Per Day | RR (95% CI) | I2 Statistic | Begg’s or Egger’s Test | |
|---|---|---|---|---|---|---|
| Martínez-Gonzáles 2014 [ | 5 | 25 g | CHD 0.94 (0.78–1.14) | 66.20% | 0.020 | NR |
| Martínez-Gonzáles 2014 [ | 3 | 25 g | Stroke 0.76 (0.67–0.86) | 0.00% | 0.440 | 0.110 |
| Schwingshackl 2017 [ | 4 | 10 g | T2DM 0.91 (0.87–0.95) | 0.00% | NR | NR |
CHD, coronary heart disease; T2DM, type 2 diabetes mellitus; RR, relative risk; NR, not reported.
Summary of linear dose-response meta-analyses of prospective studies on fish intake and CVD, CHD, stroke, T2DM, CRC, breast cancer.
| Authors, Year, Reference | No. of Studies | Each Increment Intake Per Day | RR (95% CI) | I2 Statistic | Begg’s or Egger’s Test | |
|---|---|---|---|---|---|---|
| Jayedi 2018 [ | 8 | 20 g | CVD mortality 0.96 (0.94–0.98) | 0.00% | 0.620 | NR |
| Bechthold 2017 [ | 15 | 100 g | CHD 0.88 (0.79–0.99) | 40.00% | 0.060 | NS |
| Zheng 2012 [ | 17 | 15 g | CHD mortality 0.94 (0.90–0.98) | 63.10% | 0.000 | NR |
| Bechthold 2017 [ | 15 | 100 g | Stroke 0.86 (0.75–0.99) | 25.00% | 0.180 | NR |
| Schwingshackl 2017 [ | 15 | 100 g | T2DM 1.09 (0.93–1.28) | 84.00% | NR | NS |
| Vieira 2017 [ | 11 | 100 g | CRC 0.89 (0.80–0.99) | 0.00% | 0.520 | NS |
| Schwingshackl 2018 [ | 16 | 100 g | CRC 0.93 (0.85–1.01) | 12.00% | 0.320 | 0.910 |
| Zheng 2013 [ | 11 | 15 g | Breast cancer 1.00 (0.97–1.03) | 64.00% | 0.001 | NS |
| Wu 2016 [ | 13 | 120 g | Breast cancer incidence 1.07 (0.94–1.21) | 33.30% | NR | 0.100/0.089 |
CVD, cardiovascular disease; CHD, coronary heart disease; T2DM, type 2 diabetes mellitus; CRC, colorectal cancer; RR, relative risk; NR, not reported; NS, not significant.
Summary of linear dose-response meta-analyses of prospective studies on legume intake and CHD, stroke, T2DM, CRC.
| Authors, Year, Reference | No. of Studies | Each Increment Intake Per Day | RR (95% CI) | I2 Statistic | Begg’s or Egger’s Test | |
|---|---|---|---|---|---|---|
| Bechthold 2017 [ | 8 | 50 g | CHD 0.96 (0.92–1.01) | 39.00% | 0.120 | NR |
| Bechthold 2017 [ | 6 | 50 g | Stroke 1.00 (0.88–1.13) | 62.00% | 0.020 | NR |
| Schwingshackl 2017 [ | 12 | 50 g | T2DM 1.00 (0.92–1.09) | 87.00% | NR | NR |
| Schwingshackl 2018 [ | 10 | 50 g | CRC 1.00 (0.92–1.08) | 50.00% | 0.040 | 0.590 |
| Vieira 2017 [ | 4 | 50 g | CRC 1.00 (0.95–1.06) | 33.00% | 0.200 | NS |
CHD, coronary heart disease; T2DM, type 2 diabetes mellitus; CRC, colorectal cancer; RR, relative risk; NR, not reported; NS, not significant.
Summary of linear dose-response meta-analyses of prospective studies on egg intake and CHD, stroke, T2DM, breast cancer.
| Authors, Year, Reference | No. of Studies | Each Increment Intake Per Day or Week | RR (95% CI) | I2 Statistic | Begg’s or Egger’s Test | |
|---|---|---|---|---|---|---|
| Rong 2013 [ | 9 | 1egg/day | CHD 0.99 (0.85–1.15) | 0.00% | 0.970 | >0.050/>0.050 |
| Rong 2013 [ | 8 | 1egg/day | Stroke 0.91 (0.81–1.02) | 0.00% | 0.460 | >0.050/>0.050 |
| Tamez 2016 [ | 13 | 1egg/day | T2DM 1.13 (1.04–1.22) | 85.00% | <0.001 | 0.460 |
| Keum 2015 [ | 6 | 5eggs/week | Breast cancer 1.05 (0.99–1.11) | 0.00% | 0.927 | 0.620 |
CHD, coronary heart disease; T2DM, type 2 diabetes mellitus; RR, relative risk.
Summary of linear dose-response meta-analyses of prospective studies on refined grain intake and CHD, stroke, T2DM.
| Authors, Year, Reference | No. of Studies | Each Increment Intake Per Day | RR (95% CI) | I2 Statistic | Begg’s or Egger’s Test | |
|---|---|---|---|---|---|---|
| Bechthold 2017 [ | 4 | 30 g | CHD 1.01 (0.99–1.04) | 0.00% | 0.510 | NR |
| Bechthold 2017 [ | 4 | 30 g | Stroke 1.00 (0.98–1.01) | 0.00% | 0.510 | NR |
| Schwingshackl 2017 [ | 14 | 30 g | T2DM 1.01 (0.99–1.03) | 59.00% | NR | NR |
CHD, coronary heart disease; T2DM, type 2 diabetes mellitus; RR, relative risk; NR, not reported.
Summary of linear dose-response meta-analyses on potato intake and CHD, stroke, T2DM, CRC.
| Authors, Year, Reference | No. of Studies | Total Intake Per Day | RR (95% CI) | I2 Statistic | Begg’s or Egger’s Test | |
|---|---|---|---|---|---|---|
| Schwingshackl 2018 [ | 7 | 150 g | CHD 1.03 (0.96–1.09) | 0.00% | 0.990 | NR |
| Schwingshackl 2018 [ | 6 | 150 g | Stroke 0.98 (0.93–1.03) | 3.00% | 0.400 | NR |
| Schwingshackl 2018 [ | 7 | 150 g | T2DM 1.18 (1.10–1.27) | 30.00% | 0.200 | NR |
| Schwingshackl 2018 [ | 6 | 150 g | CRC 1.05 (0.92–1.20) | 20.00% | 0.280 | NR |
CHD, coronary heart disease; T2DM, type 2 diabetes mellitus; CRC, colorectal cancer; RR, relative risk; NR, not reported.
Summary of linear dose-response meta-analyses of prospective studies on red meat intake and CVD, CHD, stroke, T2DM, CRC, breast cancer.
| Authors, Year, Reference | No. of Studies | Each Increment Intake Per Day | RR (95% CI) | I2 Statistic | Begg’s or Egger’s Test, | |
|---|---|---|---|---|---|---|
| Abete 2014 [ | 6 | 100 g | CVD mortality 1.15 (1.05–1.26) | 76.60% | <0.001 | >0.100/>0.100 |
| Bechthold 2017 [ | 3 | 100 g | CHD 1.15 (1.08–1.23) | 0.00% | 0.680 | NR |
| Bechthold 2017 [ | 7 | 100 g | Stroke 1.12 (1.06–1.17) | 0.00% | 0.500 | NR |
| Aune 2009 [ | 9 | 120 g | T2DM 1.20 (1.04–1.38) | 68.30% | 0.001 | NR |
| Feskens 2013 [ | 14 | 100 g | T2DM 1.13 (1.03–1.23) | 36.00% | NR | NR |
| Schwingshackl 2017 [ | 14 | 100 g | T2DM 1.17 (1.08–1.26) | 83.00% | NR | NS |
| Larsson 2006 [ | 14 | 120 g | CRC 1.28 (1.18–1.39) | 0.00% | 0.790 | NR |
| Alexander 2011 [ | 13 | 70 g | CRC 1.05 (0.97–1.13) | NR | <0.001 | 0.97 |
| Chan 2011 [ | 8 | 100 g | CRC incidence 1.17 (1.05–1.13) | 0.00% | 0.483 | NS |
| Vieira 2017 [ | 8 | 100 g | CRC 1.12 (1.00–1.25) | 24.00% | 0.240 | NS |
| Zhao 2017 [ | 9 | 100 g | CRC 1.16 (1.05–1.29) | 0.00% | 0.600 | NR |
| Schwingshackl 2018 [ | 21 | 100 g | CRC 1.12 (1.06–1.19) | 27.00% | 0.130 | 0.620 |
| Guo 2015 [ | 11 | 120 g | Breast cancer 1.11 (1.05–1.16) | NR | >0.100 | NR |
| Wu 2016 [ | 8 | 120 g | Breast cancer incidence 1.13 (1.01–1.26) | 56.40% | NR | 0.266/0.110 |
CVD, cardiovascular disease; CHD, coronary heart disease; T2DM, type 2 diabetes mellitus; CRC, colorectal cancer; RR, relative risk; NR, not reported; NS, not significant.
Summary of linear dose-response meta-analyses of prospective studies on processed meat intake and CVD, CHD, stroke, T2DM, CRC, breast cancer.
| Authors, Year, Reference | No. of Studies | Each Increment Intake Per Day | RR (95% CI) | I2 Statistic | Begg’s or Egger’s Test | |
|---|---|---|---|---|---|---|
| Abete 2014 [ | 6 | 50 g | CVD mortality 1.24 (1.09–1.40) | 76.40% | 0.0010 | >0.100/>0.100 |
| Wang 2016 [ | 10 | 50 g | CVD mortality 1.15 (1.07–1.24) | 75.40% | <0.0100 | ≥0.370/≥0.540 |
| Bechthold 2017 [ | 3 | 50 g | CHD 1.27 (1.09–1.49) | 0.00% | 0.5100 | NR |
| Bechthold 2017 [ | 6 | 50 g | Stroke 1.17 (1.02–1.34) | 56.00% | 0.0500 | NR |
| Aune 2009 [ | 8 | 50 g | T2DM 1.57 (1.28–1.93) | 74.00% | <0.0001 | NR |
| Feskens 2013 [ | 21 | 50 g | T2DM 1.32 (1.19–1.48) | 89.00% | NR | NR |
| Schwingshackl 2017 [ | 14 | 50 g | T2DM 1.37 (1.22–1.55) | 88.00% | NR | NR |
| Larsson 2006 [ | 11 | 30 g | CRC 1.09 (1.05–1.13) | 0.00% | 0.7800 | NR |
| Chan 2011 [ | 9 | 50 g | CRC incidence 1.18 (1.10–1.28) | 12.20% | 0.3330 | NS |
| Vieira 2017 [ | 10 | 50 g | CRC 1.18 (1.10–1.28) | 11.00% | 0.3400 | NS |
| Zhao 2017 [ | 8 | 50 g | CRC 1.22 (1.12–1.33) | 19.00% | 0.2800 | NR |
| Schwingshackl 2018 [ | 16 | 50 g | CRC 1.17 (1.10–1.23) | 6.00% | 0.3900 | 0.660 |
| Guo 2015 [ | 7 | 50 g | Breast cancer 1.09 (1.03–1.16) | NR | >0.100 | NR |
| Wu 2016 [ | 20 | 50 g | Breast cancer incidence 1.09 (1.02–1.17) | 11.80% | 0.3290 | 0.945/0.566 |
CVD, cardiovascular disease; CHD, coronary heart disease; T2DM, type 2 diabetes mellitus; CRC, colorectal cancer; RR, relative risk; NR, not reported; NS, not significant.
Summary of linear dose-response meta-analyses of prospective studies on poultry intake and CVD, CHD, stroke, T2DM, CRC, breast cancer.
| Authors, Year, Reference | No. of Studies | Each Increment Intake Per Day | RR (95% CI) | I2 Statistic | Begg’s or Egger’s Test | |
|---|---|---|---|---|---|---|
| Feskens 2013 [ | 10 | 100 g | T2DM 1.04 (0.82–1.32) | 51.00% | NR | NR |
| Shi 2015 [ | 16 | 50 g | CRC incidence 0.89 (0.81–0.97) | 41.20% | 0.043 | 0.140 |
| Shi 2015 [ | 4 | 50 g | CRC mortality 0.97 (0.79–1.20) | 0.00% | 0.695 | NR |
| Wu 2016 [ | 10 | 120 g | Breast cancer incidence 0.97 (0.85–1.11) | 33.20% | NR | 0.107/0.090 |
T2DM, type 2 diabetes mellitus; CRC, colorectal cancer; RR, relative risk; NR, not reported.
Mediterranean Diet Pyramid proposed for Italian people (MDPPI).
| Food Groups | Frequency of Intake | Serving Size (g, mL, on Average) |
|---|---|---|
| Whole grains | 1–2 servings every main meal (three meals) | 30 g |
| Fruits | 1–2 servings every main meal (three meals) | 100 g |
| Vegetables | ≥2 servings every main meal (three meals) | 100 g |
| Milk and dairy | 2–3 servings/day | Milk 50 mL |
| (preferably low-fat) | Yogurt 50 g | |
| Cheese 30 g | ||
| Nuts | 1–2 servings/day | 15 g |
| Extra Virgin Olive oil | 3–4 servings/day | 10 g |
| Herbs and spices | use them every day | |
| Fish and shellfish | ≥2 servings/week | 100 g |
| Poultry | 1–2 servings/week | 100 g |
| Legumes | ≥2 servings/week | 100 g fresh, 50 g dry |
| Eggs | 2–4 servings/week | 1 egg |
| Refined grains | ≤3 servings/week | 60 g |
| Potatoes | ≤3 servings/week | 100 g |
| Red meat | ≤2 servings/week | 100 g |
| Processed meat | ≤1 serving/week | 50 g |
| Sweets | ≤2 servings/week | 25 g |
| Red wine | ≤2 glasses/day for men | 15 g of alcohol |
| ≤1 glass/day for women |
Nutritional composition (mean of 7 days) and number of servings of weekly menu plan built on advice of Mediterranean Diet Pyramid for Italian People.
| Energy intake: 1998.85 kcal/day | |
| Carbohydrates: 246.67 g (46.3%) | |
| Protein: 82.31 g (16.5%) vegetal protein 49.27 g and animal protein 30.64 g | |
| Fats: 71.08 g (32%): SFAs 13.26 g (6.1% of total kcal), MUFAs 36.13 g, PUFAs,11.82 g | |
| Fiber: 47.48 g | |
| Ethanol: 15 g | |
| Red Wine: 5.2% of total kcal | 1 drink/day |
| Olive oil: 13.5% of total kcal | 3 servings/day |
| Potatoes: 1.9% of total kcal | 3 servings/week |
| Legumes: 6.7% of total kcal | 1 serving/day |
| Refined grains: 3.9% of total kcal | 3 servings/week |
| Whole grains: 27.4% of total kcal | 2 servings at every main meal (6 servings/day) |
| Vegetables: 5.7% of total kcal | 2 servings at every main meal (6 servings/day) |
| Fresh fruits: 11% of total kcal | 2 servings at every main meal (6 servings/day) |
| Nuts: 9.1% of total kcal | 2 servings/day |
| Processed meat: 0.9% of total kcal | 1 serving/week |
| Red Meat: 1.4% of total kcal | 2 servings/week |
| Poultry: 1.4% of total kcal | 2 servings/week |
| Milk and dairy: 4.1% of total kcal | 2 servings/day |
| Fish and shellfish: 3.5% of total kcal | 3 servings/week |
| Eggs: 1.4% of total kcal | 2 eggs/week |
| Sweets: 1.8% of total kcal | 2 servings/week |
| MAI [ | |
| Average weekly GI: 46% | |
| Average weekly GL: 115.89 | |
| Total calories provided from vegetable food: 77% | |
| Total calories provided from animal food: 23% |
SFAs, saturated fatty acids; MUFAs, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; MAI, Mediterranean Adequacy index; GI, glycemic index; GL, glycemic load.